Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Working Capital Changes (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Other Working Capital Changes data on record, last reported at -$4.7 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 71.87% year-over-year to -$4.7 million; the TTM value through Dec 2025 reached $6.4 million, up 1.17%, while the annual FY2025 figure was $6.4 million, 1.17% up from the prior year.
  • Other Working Capital Changes reached -$4.7 million in Q4 2025 per TGTX's latest filing, down from $12.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $25.6 million in Q3 2024 and bottomed at -$16.7 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is $905650.0, with a median of -$38000.0 recorded in 2021.
  • The widest YoY moves for Other Working Capital Changes: up 20336.84% in 2022, down 20336.84% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$38000.0 in 2021, then skyrocketed by 20336.84% to $7.7 million in 2022, then crashed by 160.52% to -$4.7 million in 2023, then crashed by 259.5% to -$16.7 million in 2024, then soared by 71.87% to -$4.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$4.7 million in Q4 2025, $12.2 million in Q3 2025, and -$5.7 million in Q2 2025.